Last reviewed · How we verify
NCT04908501: sPREAdPerti
Health Care Appropriateness Assessment and Support Programme at a University Hospital Centre (CHU) in Bordeaux
trial testing Intervention in Any Conditions in 63 participants. Completed in 19 September 2023.
19 September 2023
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 7 October 2021 |
| Primary completion | 19 September 2023 |
| Estimated completion | 19 September 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Intervention
Conditions studied
- Any Conditions — all drugs for Any Conditions →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Any Conditions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-appropriateness of care is a common and serious phenomenon that affects healthcare institutions in France. Appropriateness in health care is about adequacy of any type of health care with patient's needs. Relying on structuring innovative tools, the hospital university centre of Bordeaux is implementing a health care appropriateness assessment and support programme ("sPREAd pertinence"). By using a mixed method, the project's main objective is to evaluate programme effectiveness on the improvement of care appropriateness in hospital university centre of Bordeaux. Other assessments are considering impact on: specific care appropriateness indicators, care related adverse events frequency, organizational climate, and work life satisfaction. The economic impact of this program in terms of induced costs and avoided costs will be evaluated. A qualitative approach will be used to identify the programme transferability conditions with a view to produce an Operational Model for the Implementation of Appropriateness at a Healthcare Institution.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04908501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intervention
Trials testing the same drug.
- NCT07038317 — A Text Messaging Trial to Test Vaping Health Messages Optimized to Young Adults' Vaping Status · NA · not yet recruiting
- NCT06112431 — Eye Health Intervention Study in Upper Manhattan · NA · not yet recruiting
- NCT07202390 — Intraarticular Gold Microparticles for Knee Osteoarthritis · NA · not yet recruiting
- NCT07444736 — Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemica · NA · enrolling by invitation
- NCT07376668 — Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery · NA · not yet recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04908501 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 6 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04908501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing